Methyllycaconitine citrate

Methyllycaconitine citrate is a specific antagonist of α7 neuronal nicotinic acetylcholine receptor (α7nAChR) with blood-brain barrier permeability.

Product Specifications

CAS Number

[351344-10-0]

Product Name Alternative

MLA

UNSPSC

12352005

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Methyllycaconitine_citrate.html

Concentration

10mM

Purity

99.58

Solubility

DMSO : 116.67 mg/mL (ultrasonic) |H2O : 1.67 mg/mL (ultrasonic) |H2O : 2.18 mg/mL (ultrasonic; warming)

Smiles

CO[C@@H]1C(C(N(CC)C2)C3(O)[C@H]4OC)([C@@](C[C@@]5([H])[C@@H]6OC)([H])[C@@]6([H])[C@@]3(C[C@@H]5OC)O)[C@@]4([H])[C@@]2(COC(C7=C(N(C8=O)C(C[C@@H]8C)=O)C=CC=C7)=O)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O

Molecular Formula

C43H58N2O17

Molecular Weight

874.92

References & Citations

[1]Zheng X, et al. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. PLoS One. 2014 Oct 31;9 (10) :e111536.|[2]Escubedo E, et al. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J Pharmacol Exp Ther. 2005 Nov;315 (2) :658-67.|[3]Lockman PR, et al. Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. J Neurochem. 2005 Jul;94 (1) :37-44.